Danish pharmaceutical company Novo Nordisk has launched its oral weight-loss medication Wegovy in the United Arab Emirates, marking the drug's first global rollout outside the United States. The company is using the UAE market to gauge international appetite for the pill formulation of its popular weight-loss treatment.

Meanwhile, Eli Lilly's chief dealmaker indicated the pharmaceutical giant plans to pursue additional mergers and acquisitions that could expand the company into new therapeutic areas. The executive suggested investors should expect continued M&A activity as part of Lilly's growth strategy.

The developments come amid ongoing discussions about pharmaceutical pricing structures and international market dynamics. Industry observers have noted differences in how various countries approach drug pricing, with some implementing price controls while others rely more heavily on market-based mechanisms.

Both Novo Nordisk and Eli Lilly have been major players in the rapidly growing weight-loss medication market, with their products generating significant revenue and investor interest. The companies' strategic moves reflect the competitive landscape in the pharmaceutical sector as they seek to expand their global reach and therapeutic portfolios.